TY - JOUR
T1 - The Banff 2015 Kidney Meeting Report
T2 - Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology
AU - Loupy, A.
AU - Haas, M.
AU - Solez, K.
AU - Racusen, L.
AU - Glotz, D.
AU - Seron, D.
AU - Nankivell, B. J.
AU - Colvin, R. B.
AU - Afrouzian, M.
AU - Akalin, E.
AU - Alachkar, N.
AU - Bagnasco, S.
AU - Becker, J. U.
AU - Cornell, L.
AU - Drachenberg, C.
AU - Dragun, D.
AU - de Kort, H.
AU - Gibson, I. W.
AU - Kraus, E. S.
AU - Lefaucheur, C.
AU - Legendre, C.
AU - Liapis, H.
AU - Muthukumar, T.
AU - Nickeleit, V.
AU - Orandi, B.
AU - Park, W.
AU - Rabant, M.
AU - Randhawa, P.
AU - Reed, E. F.
AU - Roufosse, C.
AU - Seshan, S. V.
AU - Sis, B.
AU - Singh, H. K.
AU - Schinstock, C.
AU - Tambur, A.
AU - Zeevi, A.
AU - Mengel, M.
N1 - Funding Information:
We would like to acknowledge the instrumental support from the Roche Organ Transplantation Research Foundation Grant 608390948 awarded to Dr. Kim Solez, which allowed establishing the Banff Foundation for Allograft Pathology. The joint 2015 Banff and Canadian Transplant Society meeting acknowledges the receipt of sponsorship from Astellas, Alexion, Novartis, One Lambda, Renal Pathology Society, American Society of Transplantation, Wiley, Qiagen, Canadian Institute for Health Research, Immucor, Bridge to Life, Organ Recovery Systems, Transplant Connect, Glycorex Transplantation, Transpath Inc., and the University of Alberta.
Publisher Copyright:
© 2016 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of American Society of Transplant Surgeons
PY - 2017/1/1
Y1 - 2017/1/1
N2 - The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell–mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.
AB - The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell–mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.
KW - clinical research/practice
KW - kidney transplantation/nephrology
KW - organ transplantation in general
KW - pathology/histopathology
KW - rejection
KW - rejection: T cell mediated (TCMR)
KW - rejection: antibody-mediated (ABMR)
KW - rejection: subclinical
KW - translational research/science
UR - http://www.scopus.com/inward/record.url?scp=85008946348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85008946348&partnerID=8YFLogxK
U2 - 10.1111/ajt.14107
DO - 10.1111/ajt.14107
M3 - Article
C2 - 27862883
AN - SCOPUS:85008946348
SN - 1600-6135
VL - 17
SP - 28
EP - 41
JO - American Journal of Transplantation
JF - American Journal of Transplantation
IS - 1
ER -